Sign in

You're signed outSign in or to get full access.

XI

XWELL, Inc. (XWEL)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 revenue increased sequentially to $7.69M* from $7.02M* in Q1, but declined year over year versus $9.28M* due to the prior-year CDC surge billing normalization; operating loss was $2.7M and net loss was $2.3M .
  • Cost discipline continued: cost of sales (-5% YoY) and G&A (-9% YoY); however operating loss widened vs prior year on lower revenue despite reductions in operating expenses .
  • Strategic momentum: Orlando Magic wellness partnership, Priority Pass expansion, Yelp “Most Loved Airport Brands” recognition, new Clearwater off-airport wellness center, redesigned website, and Penn Station build-out .
  • Biosecurity tailwind: CDC Traveler-based Genomic Surveillance (TGS) program extended for three years; management noted recognition by incoming administration and related funding legislation .
  • No explicit financial guidance was provided for Q3/Q4; management emphasized operational execution and profitability focus. S&P Global consensus EPS and revenue were unavailable for comparison (S&P Global).

What Went Well and What Went Wrong

What Went Well

  • Sequential topline growth with category mix improvement and continued cost discipline; CEO: “focused, multi-pronged strategy to expand our operational footprint…already delivering measurable results” .
  • Brand and channel momentum: Official wellness spa of the Orlando Magic; recognition by Yelp; Priority Pass expansion broadening access across U.S. and international locations .
  • Off-airport expansion: New Clearwater wellness center opened; Penn Station tech-forward destination progressing; redesigned XWELL.com integrates brands and booking .

What Went Wrong

  • Year-over-year revenue decline ($7.69M* vs $9.28M*) driven by normalization of CDC surge billing in Q2 2024; operating loss widened to $2.7M (vs $1.9M prior year) despite lower expenses .
  • Profitability remains a challenge: Q2 net loss was $2.3M; EBITDA margin contracted vs prior year; earnings call reiterated ongoing efforts to enhance operational processes .
  • No guidance ranges provided (revenue, margins, EPS), limiting visibility; first quarter carried elevated one-time costs and a timing impact on CDC program revenue .

Financial Results

MetricQ2 2024Q1 2025Q2 2025
Revenue ($USD Millions)$9.28M*$7.02M* $7.69M*
Operating Loss ($USD Millions)$1.90M $3.20M $2.70M
Net Income - (IS) ($USD Millions)-$2.00M -$4.70M -$2.27M
Diluted EPS - Continuing Operations ($USD)-$0.48*-$1.00*-$0.56*
Gross Margin (%)33.17%*18.78%*23.07%*
EBITDA ($USD Millions)-$1.65M*-$2.99M*-$2.51M*
EBITDA Margin (%)-17.73%*-42.60%*-32.58%*
Net Income Margin (%)-21.50%*-67.19%*-29.51%*

Values marked with an asterisk were retrieved from S&P Global.

Segment revenue mix

SegmentQ1 2025 ($USD Millions)Q2 2025 ($USD Millions)
XpresSpa$4.30M $4.90M
XpresCheck/XpresTest (incl. HyperPointe)$2.20M $2.20M
Naples Wax Center$0.55M $0.65M

KPIs and liquidity

MetricQ1 2025Q2 2025
Cash and Equivalents ($USD Millions)$3.70M $5.30M
Marketable Securities ($USD Millions)$7.30M $2.90M
Total Current Assets ($USD Millions)$14.80M $11.80M
Long-term Debt ($USD)$0 $0

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueQ3/Q4 2025Not providedNot providedMaintained (no guidance issued)
Margins/OpEx/Tax RateFY 2025Not providedNot providedMaintained (no guidance issued)
Segment-specific guidanceFY 2025Not providedNot providedMaintained (no guidance issued)
Dividends/Capital returnsFY 2025Not providedNot providedMaintained (no guidance issued)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024, Q1 2025)Current Period (Q2 2025)Trend
CDC TGS program3-year extension; contract base $53.7M, ceiling $85.7M; critical biosecurity role Recognized by incoming administration; funding included in legislation Strengthening policy support
Off-airport expansionNaples Wax Estero opened; plan for 6 additional Florida locations in 2025 Clearwater wellness center opened; flexible memberships; MedSpa acquisitions targeted in Orlando/Dallas/Salt Lake City Accelerating footprint
Transportation hubsPenn Station opening planned mid-2025 Penn Station tech-forward destination preparing to open Execution progressing
Digital/customer experienceHyperPointe platform; CRM and brand unification Redesigned XWELL.com integrating brands and booking Platform upgrade complete
Partnerships/Brand equityPriority Pass revenue stream began; CDC renewal Priority Pass expanded; Orlando Magic partnership; Yelp recognition Broadening access and visibility
Cost discipline/profitabilityReduced operating expenses 2024; Q1 2025 OpEx -11% YoY Q2 2025 cost of sales -5% YoY; G&A -9% YoY; focus on execution Ongoing efficiency work

Management Commentary

  • CEO: “We are currently executing a focused, multi-pronged strategy to expand our operational footprint…We believe that these efforts are already delivering measurable results” .
  • CEO on brand and partnerships: Orlando Magic official wellness spa; Priority Pass expansion; Yelp recognition; redesigned unified digital platform .
  • CEO on biosecurity: TGS program recognized by incoming administration; company is a vital contributor to national public health and early warning for pathogens .
  • CFO: Q2 revenue $7.7M; segment mix ($4.9M XpresSpa, $2.2M XpresCheck/HyperPointe, $0.65M Naples Wax); operating loss $2.7M; net loss $2.3M; liquidity $5.3M cash, $2.9M marketable securities, no long-term debt .
  • CFO: Year-over-year revenue decline due to prior-year surge billing at airports above base contract amounts with the CDC .

Q&A Highlights

  • No Q&A session was held on the call; prepared remarks only; the conference concluded after management commentary .

Estimates Context

  • S&P Global consensus EPS and revenue estimates for Q2 2025 were unavailable; thus, we cannot benchmark reported results versus consensus. Values retrieved from S&P Global.
  • Given sequential improvement and stabilizing CDC program revenues post-extension, we expect sell-side models to reassess segment mix and operating loss trajectory; however, absent guidance, revisions may remain conservative until visibility improves .

Key Takeaways for Investors

  • Sequential revenue growth and improved gross margins vs Q1* alongside cost reductions indicate operational progress, though profitability remains challenged .
  • The CDC TGS extension and policy recognition provide durable program visibility; normalization from prior surge billing explains YoY revenue decline .
  • Strategic expansion beyond airports—Clearwater opening, Penn Station build-out, targeted MedSpa M&A—broadens TAM and diversifies revenue streams .
  • Partnerships (Orlando Magic, Priority Pass) and brand equity (Yelp recognition) enhance demand capture and marketing leverage .
  • Liquidity improved quarter over quarter with higher cash and no long-term debt; capacity for targeted investment remains while maintaining discipline .
  • Near term, the narrative hinges on execution: ramping off-airport centers, delivering Penn Station, and translating brand initiatives into margin improvement; absence of guidance may cap immediate estimate revisions .
  • Medium term, tighter cost control plus diversified wellness channels could compress operating losses; watch for proof points in segment growth, membership uptake, and CDC program run-rate stabilization .

Values marked with an asterisk were retrieved from S&P Global.

References: earnings press release and 8-K ; earnings call transcript ; prior quarter press release (Q1 2025) ; FY 2024 press release .